UMeWorld Releases Clinical Results: DAG Oil Shows Significant Reductions in Uric Acid, Cholesterol, Triglycerides, and Weight

Rhea-AI Summary

UMeWorld (OTC: UMEWF) has announced positive clinical results for its DAG oil-based cooking oil brand, DAGola. The study, involving 820 overweight adults with elevated blood glucose levels, demonstrated significant health improvements after using DAG oil in home-cooked meals. After two months, participants showed:

- Significant reductions in uric acid (P < 0.01)
- Decreased total cholesterol (P < 0.01) and LDL-C (P < 0.05)
- Marked reduction in triglycerides (P < 0.001)
- Significant drops in weight and BMI (P < 0.01)

Of the initial 820 participants, 415 completed the two-month program. DAGola offers four DAG-based oil blends: Gourmet, Vitality, Master Chef, and Premium, containing up to 50% fewer triglycerides than conventional oils. The products are available through the company's website and Amazon.

Positive

• Clinical study demonstrated significant health benefits across multiple metabolic markers
• Large-scale study with 820 participants validates product efficacy
• Product already commercially available through multiple channels
• Proprietary enzymatic technology provides higher DAG content than natural alternatives
• Multiple product variants available for different market segments

Negative

• High study dropout rate (49.4%) may raise concerns about product adoption
• Study required strict dietary control, limiting real-world applicability
• Results limited to 2-month timeframe, lacking long-term efficacy data

MIAMI, May 06, 2025 (GLOBE NEWSWIRE) -- UMeWorld Limited (OTC: UMEWF) today announced the results of a clinical study demonstrating the metabolic benefits of diacylglycerol (DAG) oil, the active ingredient in its functional cooking oil brand, DAGola. The study confirmed that regular consumption of DAG oil led to significant improvements in key health markers, including uric acid, triglycerides, cholesterol, and body weight.

The study, titled “The study on the effects of diacylglycerol (DAG) oil in patients with elevated blood glucose levels and overweight”, was conducted with 820 adult participants aged 18 to 75 who were overweight (BMI > 24.0 kg/m²) and had either glycated hemoglobin (HbA1c) levels ≥ 5.7% or fasting blood glucose ≥ 5.6 mmol/L. Participants agreed to adopt a structured dietary intervention that included exclusive use of DAG oil in home-cooked meals. Dining out was prohibited during the study period in order to tightly control dietary intake.

A total of 415 participants completed the two-month program. The dropout rate was higher than anticipated, largely due to difficulty adhering to the no–dining out requirement, highlighting the role of eating habits in long-term nutritional interventions.

Clinical results were analyzed using the paired-sample T-test method. After one month of DAG oil consumption, participants with elevated levels saw significant reductions in uric acid (P < 0.01), total cholesterol (P < 0.01), and LDL-C (P < 0.05). After two months, weight and BMI dropped significantly (P < 0.01), uric acid remained significantly reduced (P < 0.01), and triglyceride levels showed a marked decrease (P < 0.001).

These results suggest that DAG oil can contribute meaningfully to improving metabolic balance, particularly in populations at risk for hyperuricemia, dyslipidemia, obesity, and early-stage insulin resistance. The findings position DAGola not only as a premium culinary oil, but as a functional nutrition solution backed by clinical evidence.

Metabolic disease affects hundreds of millions of people worldwide. Often rooted in diet and lifestyle, conditions like type 2 diabetes, obesity, and cardiovascular disease are largely preventable - and in many cases, reversible. Functional foods like DAGola offer a practical, everyday way to help individuals take control of their health, starting in their own kitchens.

“This study validates the science behind DAGola,” said Michael Lee, CEO of UMeWorld. “For too long, consumers have had to choose between flavor, convenience, and genuine health benefits. We believe it’s time for that to change. Our mission with DAGola is to make advanced nutrition effortless - by putting clinically supported, high-performance oils in kitchens everywhere. DAGola isn’t just another cooking oil; it’s a daily upgrade to metabolic wellness, backed by real science and crafted with care. We’re proud to offer a product that delivers measurable benefits in everyday use - without compromising on taste or quality.”

DAGola offers 4 high-performance DAG-based oils: Gourmet Blend, Vitality Blend, Master Chef Blend and Premium Blend. Each is crafted for culinary excellence and metabolic support, with select blends delivering up to 50% fewer triglycerides than conventional oils. While small amounts of DAG occur naturally in oils like olive oil - typically less than 3% - DAGola products are specially formulated using a proprietary enzymatic technology to provide a significantly higher DAG content for enhanced wellness benefits. Available online at www.cellugizer.com or amazon.com/dagola.

About UMeWorld

UMeWorld is redefining the cooking oil industry through science and innovation. Our flagship product, DAGola™, contains up to 50% less triglycerides than traditional oils and is clinically proven in multiple human trials to support heart health and improve lipid metabolism. Using a proprietary enzymatic technology, we produce functional oils that help combat metabolic syndrome, which affects over 47 million Americans. This same advanced process also converts palm and used cooking oils into eco-friendly biofuels. Our mission is to lead in next-generation nutrition and sustainable energy, delivering innovation with real-world impact.

About DAGola Inc.

DAGola Inc. is the U.S. branch of UMeWorld Limited. It focuses on selling innovative food products in North America. To learn more about DAGola Inc., visit www.dagolaoil.com.

Forward-Looking Statements

This press release may contain forward-looking statements, about UMeWorld's expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, UMeWorld or its representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as "believe," "expect," "intend," "plan," "may," "should" or "anticipate" or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by UMeWorld with the U.S. Securities and Exchange Commission, press releases or oral statements made by or with the approval of one of UMeWorld's authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause UMeWorld's actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause UMeWorld's actual activities or results to differ materially from the activities and results anticipated in such forward-looking statements, including, but not limited to, the factors summarized in UMeWorld's filings with the SEC. In addition, UMeWorld operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond its control. UMeWorld does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise. Please see the risk factors associated with an investment in our securities which are included in our Annual Report on Form 20-F and other periodic and current reports filed with the Securities and Exchange Commission.

Contact:
Michael Lee
UMeWorld Limited
Email: info@umeworld.com

FAQ

What are the main health benefits of UMeWorld's (UMEWF) DAG oil according to the clinical study?

According to the clinical study, DAG oil showed significant reductions in uric acid, total cholesterol, LDL-C, triglycerides, and body weight/BMI in participants over a two-month period.

How many participants completed UMeWorld's DAG oil clinical trial?

Out of 820 initial participants, 415 completed the two-month program, with dropouts mainly due to difficulty adhering to the no-dining out requirement.

What different types of DAGola cooking oil products does UMeWorld offer?

UMeWorld offers four DAG-based oil varieties: Gourmet Blend, Vitality Blend, Master Chef Blend, and Premium Blend, with up to 50% fewer triglycerides than conventional oils.

Where can consumers purchase UMeWorld's DAGola cooking oil?

DAGola cooking oil is available for purchase online through www.cellugizer.com and amazon.com/dagola.

What makes UMeWorld's DAGola different from regular cooking oils?

DAGola uses proprietary enzymatic technology to provide significantly higher DAG content (compared to less than 3% in natural oils like olive oil) for enhanced wellness benefits.